Hirokazu Nagai, MD, PhD
Center/Department
Clinical Research Center
Director, Department of Hematology and Oncology Research
Chief, Division of Administration
Interest
clinical hematology, clinical oncology, (chemotherapy, stem cell transplantation) molecular biology
Area of Research
Clinical and molecular hemato-oncology
Contact Information
Hirokazu Nagai, MD, PhD
Laboratory of Adbanced Therapy
Department of Hematology and Oncology Research
Clinical Research Center
National Hospital Organization Nagoya Medical Center
4-1-1 Sannomaru, Naka-ku, Nagoya
Aichi 460-0001, Japan
Tel: +81-52-951-1111
Fax: +81-52-951-0664
Email: nagaih[at]nnh.hosp.go.jp
Preferred contact method: e-mail
Research
Development of new therapeutic strategy against malignant lymphoma including AIDS-related lymphoma.
Molecular diagnmosis of minimal residual diseases of malignant lymphoma
Biography
M.D. Kanazawa University, School of Medicine, 1985
Ph.D. Nagoya University, School of Medicine, 1993
1985 graduated from Kanzawa University, School of Medicine
1985-1988 Nagoya National Hospital (clinical resident)
1988-1989 Toyohashi National Hospital (clinical staff)
1989-1990 Tokyo Metropolitan Komagome Hospital (clinical staff)
1990-1992 National Cancer Center, Research Institute (research resident)
1992-1993 Nagoya University Hospital (clinical staff)
1993-1995 Jefferson Cancer Institute (USA) (postdoctoral fellow)
1995-2001 Nagoya University Hospital (clinical staff)
2001-present Nagoya Medical Center (clinical staff)
2002-present Nagoya Medical Center (director of department of hematology/oncology research)
Selected Publications
Nagai H, et al.
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma
Eur J Haematol. 86:117-123, 2011
Nagai H, et al
Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.
Eur J Haematol. 84:499-505, 2010
Hagiwara K, Nagai H. et al.
Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma
Leukemia Res. 34: 50-54, 2010
Terasawa T and Nagai H
Current clinical evidence on interim FDG-PET for advanced-stage Hodgkin’s lymphomaand diffuse large B-cell lymphoma to predict treatment outcomes
Leukemia Lymphoma. 50; 1750-1754, 2009
Terasawa T, Nagai H et al.
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin’s Lymphoma and DiffuseLarge B-cell Lymphoma: A Systematic Review
J Clin Oncol. 27; 1906-1914, 2009
Nagai H. et al.
Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma
British J Haematol. 143: 672-680, 2008
Nagai H et al.
Actual status of AIDS-related lymphoma management in Japan.
Int J Hematol. 87: 442-443, 2008
Terazawa T, Nagai H. et al.
Fluorine-18-fluorodeoxyglucose positron emission tomography for post-therapy assessment of Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphpoma.
J Nucl Med 49: 13-21, 2008
